The JUXTAPID® Risk Evaluation and Mitigation Strategy (REMS)  

1. Prescribers are educated about: 

  • The approved indication for JUXTAPID
  • The risk of hepatotoxicity associated with the use of JUXTAPID
  • The need to monitor patients during treatment with JUXTAPID, as per the product labeling   

2. JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia

3. Patients are informed about the risk of hepatotoxicity associated with the use of JUXTAPID and the need for baseline and periodic liver monitoring


All prescribers of JUXTAPID must become certified in the JUXTAPID REMS.

The 3-step process for Prescriber Certification is outlined below: 

1. Review the JUXTAPID Prescribing Information and the Fact Sheet

2. Complete the online Prescriber Training Module and Prescriber Enrollment Form

3. Agree to counsel each patient using the Patient Guide, and to complete a Patient-Prescriber Acknowledgement Form with each patient


Homozygous Familial Hypercholesterolemia

JUXTAPID is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDLC), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Limitations of Use

  • The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH).
  • The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined.

For additional information about JUXTAPID REMS, please call 1-85-JUXTAPID (1-855-898-2743)